A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Inclusion Criteria

• •Parts A and B only:
• •* Participants must be less than or equal to (≤)18 years of age.
• •* Body weight greater than or equal to (≥)10 kilograms and body surface area (BSA) ≥0.5
• •* Participants with any relapsed/refractory malignant solid tumor (excluding lymphoma), including central nervous system tumors, that have progressed on standard therapies.
• •* For sites that are actively enrolling Parts B and C, participants with neuroblastoma who are eligible for Part C will be excluded from Part B unless approved by Lilly CRP/CRS.
• •Part C only:
• •* Participants must be less than (\<) 21 years of age.
• •* Participants have a BSA ≥0.2 m².
• •* Participants with first relapse/refractory neuroblastoma.
• •All Parts
• •* Participants must have measurable or evaluable disease by RECIST v1.1 or RANO.
• •* A Lansky score ≥50 for participants \<16 years of age or Karnofsky score ≥50 for participants ≥16 years of age.
• •* Participants must have discontinued all previous treatments for cancer or investigational agents and must have recovered from the acute effects to Grade ≤1 at the time of enrollment.
• •* Able to swallow and/or have a gastric/nasogastric tube.
• •* Adequate hematologic and organ function ≤2 weeks (14 days) prior to first dose of study drug.
• •* Females of reproductive potential must have negative urine or serum pregnancy test at baseline (within 7 days prior to starting treatment).
• •* Female participants of reproductive potential must agree to use highly effective contraceptive precautions during the trial. For abemaciclib, females should use contraception for at least 3 weeks following the last abemaciclib. For other study drugs, highly effective contraceptive precautions (and avoiding sperm donation) must be used according to their label.
• •* Life expectancy of at least 8 weeks and able to complete at least 1 cycle of treatment.
• •* Caregivers and participants willing to make themselves available for the duration of the trial.